Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

701.23 +18.30 (+2.68%)
Official Closing Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Best Growth Stock ETF to Invest $100 in Right Now
This ETF has outperformed the S&P 500 handily over various multi-year periods. 
Via The Motley Fool
Topics ETFs Stocks
1 Beaten-Down Stock That Could Soar by the End of the Year
The drugmaker has a major catalyst on the way. 
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
The drugmaker's recent dip could also be a buying opportunity. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years. 
Via The Motley Fool
A Look Into Eli Lilly Inc's Price Over Earnings
 
Via Benzinga
Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs
Via Stocktwits
Jim Cramer Says Don't Quit Market When It's Frothy: 'Is Widespread Irrationality a Reason To Sell Down in Perfectly Rational Stocks? Absolutely Not'
In the face of a frothy market, Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market's irrationality. 
Via Benzinga
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
This Red-Hot Vanguard ETF Just Hit an All-Time High. Here's Why It's Still Worth Buying in August.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks. 
Via The Motley Fool
Topics ETFs
Why Novo Nordisk Flew Almost 3% Higher on Friday
It seems to be holding off on price adjustments demanded by President Trump. 
Via The Motley Fool
Topics Government
Why Eli Lilly (LLY) Stock Is Up Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.2% in the afternoon session after the stock extended its positive momentum partly fueled by reports of major insider buying by top... 
Via StockStory
Topics Artificial Intelligence
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price target. 
Via Benzinga
UnitedHealth's Best Day Since 2008, Intel's Best Weekly Gain In Decades: What's Moving Markets Friday?
Major tech-heavy indices edged lower from record highs by midday Friday in New York, as investors adopted a cautious stance ahead of the Trump-Putin meeting and after data showed a dip in consumer... 
Via Benzinga
Topics Economy
Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up
Via Benzinga
Guidance Watch: 2 Companies Bullishly Raising Forecasts
Several companies, including Palantir and Eli Lilly, have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters. 
Via Talk Markets
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other... 
Via Benzinga
Topics Artificial Intelligence
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Stay informed with the top movers within the S&P500 index on Thursday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
This Chinese EV-Maker Gets A Price Target Hike From JPMorgan, But Retail’s Concerned About The Stock’s Performance
JPMorgan lifted fiscal 2026 and 2027 volume estimates for Nio by 11% to 13% on stronger volume from the company's new L90 and L80 SUV launches. 
Via Stocktwits
Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720
According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 
Via Stocktwits
Topics Government World Trade
Eli Lilly Hikes UK Mounjaro Price By Up To 170% As Trump Pressure Mounts
President Donald Trump is moving ahead with his Most Favored Nation pricing plan and Eli Lilly is playing ball. 
Via Investor's Business Daily
Topics Government
These S&P500 stocks are moving in today's session
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Eli Lilly & Co.: Deep Pullback Near 52‑Week Low Tests Strong Fundamentals And Bullish Analyst Targets
LLY has given back meaningful ground over recent horizons: the stock is down approximately $103.94 (≈-13.6%) month-to-date and about $119.68 (≈-15.4%) year-to-date. 
Via Talk Markets
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market. 
Via Benzinga
5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed... 
Via StockStory
Topics Earnings
3 Market-Beating Stocks to Keep an Eye On
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the... 
Via StockStory
Why Eli Lilly Stock Popped Today
The GLP-1 weight loss wars have gone global. 
Via The Motley Fool
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock... 
Via StockStory
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs. 
Via Benzinga
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.